[{"id":"2d71fd15-e727-4338-8ce7-c1e33e2ba3b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04857372","created_at":"2021-09-30T12:52:53.152Z","updated_at":"2024-07-02T16:35:03.740Z","phase":"Phase 1","brief_title":"A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors","source_id_and_acronym":"NCT04857372","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" LATS1 • LATS2","pipe":" | ","alterations":" LATS1 mutation • LATS2 mutation","tags":["LATS1 • LATS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LATS1 mutation • LATS2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IAG933"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 10/06/2025","primary_completion_date":" 10/06/2025","study_txt":" Completion: 10/06/2025","study_completion_date":" 10/06/2025","last_update_posted":"2024-05-14"},{"id":"f94513c7-17ef-4994-b08f-51b6b5cb561e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05789602","created_at":"2023-03-29T14:03:26.969Z","updated_at":"2024-07-02T16:35:20.284Z","phase":"Phase 1","brief_title":"A Study of BPI-460372 in Advanced Solid Tumor Patients","source_id_and_acronym":"NCT05789602","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" LATS1","pipe":" | ","alterations":" LATS1 mutation","tags":["LATS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LATS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BPI-460372"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 04/24/2023","start_date":" 04/24/2023","primary_txt":" Primary completion: 04/17/2025","primary_completion_date":" 04/17/2025","study_txt":" Completion: 04/17/2026","study_completion_date":" 04/17/2026","last_update_posted":"2024-02-08"}]